98 Views | 70 Downloads
Daniel L. Drane ddrane@emory.edu
Nigel P. Pedersen npeders@emory.edu
DD and NP created an outline for the article, wrote major components, and invited and supervised co-authors with specific expertise in relevant areas to write subsections of the paper. All authors were given an opportunity to edit the manuscript prior to submission for publication.
DD and NP planned the paper, created an outline, recruited co-authors to assist with writing specific subsections, wrote several subsections of the paper, and provide editorial oversight. DS, CB, AD, AA, and AK were assigned subsections to write based on their specific expertise, carried out systematic literature searches, and prepared a draft of their assigned section. All co-authors contributed to the editorial process. All authors contributed to the article and approved the submitted version.
DD receives ongoing funding from Medtronic, Inc. to run a Core Analysis Lab for neuroimaging and cognitive testing in one of their FDA trials, these funds did not contribute in any form to his role in this paper. They were not involved in this paper in any manner, including study design, data collection, analysis, or interpretation, the writing of this article or the decision to submit it for publication. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
We would like to thank our undergraduate students, Noah Okado and Rogelio Cortez-Cuevas, with their assistance in the preparations of Figures 7, ,8,8, and our neurophilosophy collaborators, Drs. Anne Cleary and Joseph Neisser for contributing ideas related to our use of a deja vu assessment task.
DD's efforts on this paper were supported in part by funding received from the National Institutes of Health/National Institute of Neurological Disorders and Stroke (NIH/NINDS, R01NS088748). He also receives funding from additional grants from the NIH (R01MH118514; R01NS110347), as well as Medtronic, Inc. (A1321808). NPP was supported in part by funding received from the NIH/NINDS (K08NS105929) and CURE Epilepsy.
© 2021 Drane, Pedersen, Sabsevitz, Block, Dickey, Alwaki and Kheder.